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Abstract
Pulmonary hypertension (PH) is a progressive disease that causes high patient mortality. With
limited hemodynamic reserve, many PH patients require maintenance IV infusion medications
to maintain their activities of daily living. One common delivery method for this targeted
therapy is through a Remodulin® (treprostinil) pump. When presenting for emergent
evaluation, decompensating PH patients have a broad differential diagnosis including pump
failure. PH patients are at a high risk of poor patient outcomes given the difficulty in
recognizing PH-specific symptoms and unique aspects of their management. Therefore,
learners will benefit from participating in an immersive simulation-based PH patient scenario
in a safe learning environment. Here, we present a simulated scenario of a decompensating PH
patient on a Remodulin® pump.
Categories: Emergency Medicine, Medical Education, Medical Simulation
Keywords: remodulin, pulmonary hypertension, simulation, critical care, pulmonary critical care,
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Introduction
Pulmonary hypertension (PH) is a progressive disease that causes high patient mortality. It is
defined as a mean pulmonary artery pressure of ≥25 mm Hg at rest [1]. PH includes a
heterogeneous group of disorders that are differentiated based on clinical, hemodynamic, and
histopathologic features including embolic, respiratory, venous, and arterial disease [2]. The
estimated prevalence of PH is about 1% of the global population, which increases up to 10% in
individuals above the age of 65 [3]. Patients suffer from high mortality secondary to severely
blunted hemodynamics and little pulmonary reserve, with an overall 58% survival rate at three
years [4]. In addition, patients experience difficulty in performing daily tasks due to shortness
of breath, swelling of the legs and abdomen, and progressive fatigue. While recent advances in
care have improved PH patients' quality of life, few measures are truly curative.
One subset of PH, pulmonary arterial hypertension (PAH) occurs when elevated pressures are
caused by an obstructive environment in the small arteries of the lung. The cause is often
unknown but can be due to medications, HIV infection, connective tissue/autoimmune
disorders, and other related factors [5]. Targeted therapies have shown benefits in impacting
PAH patients' functional status and daily living conditions. Remodulin®, an IV infusion of
treprostinil, is one such therapy used in the treatment of PAH. It acts through the direct
vasodilation of pulmonary arterial vascular beds. This reduces pulmonary arterial pressures,
therefore increasing cardiac output (CO) and systemic oxygen distribution. These effects are
achieved while having minimal effect on heart rate [6,7]. Simonneau et al. found that
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Remodulin® improved symptom relief and hemodynamics compared to placebo with a
composite week 12 post-treatment baseline of 8.5±0.5 compared to 7.4±0.2 in placebo,
p<0.0001 [8]. Side-effects from medications like Remodulin® often stem from the mode in
which they are delivered and their mechanism. These can range from a mild sensation of
feeling flushed to severe infusion site discomfort. Given its roughly four hour half-life, abrupt
cessation of Remodulin® can cause noticeable hemodynamic compromise in as early as two
hours [9]. Up to 10% of patients in the initial 2017 Remodulin® study had some form of pump
failure after four years and 33% had no corresponding alarm to alert them [10]. Abrupt pump
failure leads to PH patients presenting in extremis with progressive symptoms of dyspnea,
edema, angina and signs such as tachycardia, hypoxia, and hypotension [10,11].
The profound variability among PH patients' baseline vital signs and clinical exams makes it
difficult for providers to recognize acute changes. Even more challenging for the treating
provider is the nuanced nature of the targeted therapies. Suboptimal treatment due to the
misunderstood and unique pathology of PAH can worsen the patient’s clinical condition and
must be avoided at all costs. Kingman et al. interviewed over 100 PH nurses and clinicians and
found that 68% of respondents reported serious or potentially serious errors in PAH medication
administration [12]. This study highlights the need for standardization of hospital treatment
protocols and the need for further education in clinical training environments [12]. Optimal
treatment typically includes limiting fluid resuscitation to 250 mL and is only indicated if the
patient is dehydrated. Maximization of oxygenation is imperative. Use of non-invasive
oxygenation (non-rebreather, high-flow nasal cannula) should be the initial resuscitation
strategy to limit hypoxia. Vasopressors should be utilized early to maintain adequate oxygen
delivery. If these modes fail, only then should more invasive modes of positive pressure
ventilation be used with the lowest possible pressures [13]. Early communication and inclusion
of PH coordinators and specialists is essential. The purpose of this simulation is to provide a
guide for learners to recognize the signs and symptoms of a crashing PH patient, familiarize
themselves with the common medications and various available pumps, understand the
intricacies of a patient presenting with Remodulin® pump failure, and acquire the appropriate
management skills needed to improve patient outcomes and prevent patient harm.
Technical Report
This simulation scenario is designed to occur in a rural emergency setting. Department
capabilities include ability for advanced cardiac life support with standard airway resources,
defibrillator and code cart, continuous ECG and vital sign monitoring, and a high-fidelity
simulator. Learners have access to all standard code cart medications as well as laboratory
studies and radiography. Given the rural environment, hospital specialists are only available via
consultant calls to surrounding outside hospitals.
Along the patient’s left waistband, we secured the subcutaneous or IV Remodulin® pump, and
connected this to the mannequin by the pump tubing. We obtained the CADD-Legacy® 1
(Smiths Medical, Inc., St. Paul, MN, USA) IV Remodulin® pump and the CADD-MS™ 3 (Smiths
Medical, Inc., St. Paul, MN, USA) subcutaneous pump from our hospital’s PH team (Figures 1-4).
The PH team has extra pumps available to coach new PH patients on how to replace medication
cartridges and connect IV tubing to their access site.
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FIGURE 1: Intravenous Remodulin® pump supplies
CADD-Legacy® 1 pump with IV tubing, central line supplies, and Tegaderm™ film
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FIGURE 2: Intravenous Remodulin® pump mannequin setup
Simulation mannequin setup with CADD-Legacy® 1 pump, IV tubing, central line supplies, and
Tegaderm™ film
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FIGURE 3: Subcutaneous Remodulin® pump supplies
CADD-MS™ 3 pump with subcutaneous tubing and 3-mL medication syringe
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FIGURE 4: Subcutaneous Remodulin® pump mannequin setup
Simulation mannequin with CADD-MS™ 3 pump setup, subcutaneous tubing, and 3-mL medication
syringe
Other options for potentially obtaining a pump for the simulation include contacting the
manufacturer of Remodulin® directly or the pharmacies that supply Remodulin®. To maintain
the appearance of a fully functional Remodulin® pump, we cut a 1 by 1 inch square piece of
silver cardstock to fit to size and glued it onto the screen. On this cardstock, we drew the
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appearance of a full battery and the patient's continuous rate (Figure 3). We then covered the
cardstock with a piece of clear plastic template (used in quilting supplies) and glued this
directly above the cardstock. On the back of the pumps we taped the name of a pharmacy and
phone number (our simulation center phone number), which, if noted, would allow the learner
to call for the patient’s weight for dosing and concentration of medications. Most patients have
this information on the back of their pumps as well.
Preparing the mannequin for the simulation
Materials Included
High-fidelity adult mannequin
Remodulin® pump - option A or option B
1 x 1 inch piece of silver cardstock
1 x 1 inch piece of clear plastic template
CADD® Extension Set - male luer, clamp, 0.2µ air-eliminating filter, and anti-siphon valve with
male luer
3-mL Smiths Medical (St. Paul, MN, USA) medication syringe
Central IV line supplies
Tegaderm™ film (3M, Inc., St. Paul, MN, USA)
Application of IV Remodulin® CADD-Legacy® 1 pump to
simulator - option A
Remove the white cap off the CADD-Legacy™ 1 IV Remodulin® pump
Remove the clear cap from the male end of the extension tubing and connect this to the female
end of the CADD-Legacy™ 1 IV Remodulin® pump
Cut the central IV line near the white suture hub and cover it with Tegaderm™ onto the
mannequin (Figures 1, 2)
Remove the blue cap from the other male end of the extension tubing and connect this to the
female end of a central IV catheter
Fasten the Remodulin® pump to mannequin’s waistband
Application of subcutaneous CADD-MS™ 3 pump to simulator -
option B
Remove the black cap off the CADD-MS™ 3 device
Remove the syringe tail from the 3-mL medication container
Place the 3-ml syringe body into the device with the male end up (Figure 3)
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Attach the black cap over the 3-mL syringe
Attach the female end of the extension tubing onto the exposed male portion of the 3-mL
syringe
Connect the subcutaneous portion of the tubing to the mannequin and cover it with
Tegaderm™ (Figure 4)
Fasten the Remodulin® pump to mannequin’s waistband
Preparing the simulation scenario
This case requires two or three embedded participants: a nurse and an emergency medical
technician (EMT), with or without the addition of a family member to assist with history. A
simulation technician is needed to run the case and voice the mannequin, and a faculty
member should be present to lead the debriefing. All personnel should be pre-briefed and
familiar with the case outline, the case flowchart, shown in Figure 5, the case branch point vital
signs given in Table 1, and its associated clinical images (Figures 6-8). This case has several
critical actions to stabilize the patient as demonstrated by the green pathway in the flowchart.
The red pathway indicates improper interventions from which the learner has an opportunity to
recover before the case is terminated.
FIGURE 5: Flow chart showing correct and incorrect scenario
branch points
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ACLS, advanced cardiac life support; NRB, non-rebreather; HFNC, high-flow nasal cannula; OSH,
outside hospital; ICU, intensive care unit
 Heart rate Blood pressure Temperature (°F) O2 saturation RR
#1 98 92/54 97.3 84% (4 L NC) 30
#2 106 80/48 97.3 80% (4 L NC) 34
#3 90 98/60 97.3 92% (>6 L HFNC or NRB) 25
#4 60 64/32 97.3 72% (4 L NC) 46
#5 80 104/68 97.3 96% (>6 L HFNC or NRB) 18
#6 0 0 97.3 Undetectable 0
TABLE 1: Vital signs
NC, nasal cannula; HFNC, high-flow nasal cannula; NRB, non-rebreather; RR, respiratory rate
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FIGURE 6: Chest X-ray of a patient with pulmonary
hypertension
The X-ray depicts cardiomegaly (black arrow), increased right ventricular diameter (blue arrow),
pulmonary congestion (red arrow), and central venous access (green arrow)
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FIGURE 7: Echocardiogram of a patient with pulmonary
hypertension
The echocardiogram shows right ventricular dilation (red arrows)
FIGURE 8: Electrocardiogram of a patient with pulmonary
hypertension
The electrocardiogram shows right axis deviation (red arrows), prominent R wave in V1 and S wave
in V5 (blue arrows)
Pre-briefing
Prior to initiating the case, all learners were pre-briefed on the mannequin’s capabilities and
the resources available to them during the case. They were instructed to assign a team leader
and to approach the mannequin as if this were a real patient. Given the complexity of the case,
a broad differential must be worked through quickly and efficiently. We opted to deliver this
simulation education during our upper level resident simulation curriculum.
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Pulmonary hypertension case
A 37-year-old female with a history of mixed connective tissue disorder and stage IV PH
presents by EMS with chief complaint of shortness of breath and chest pain. EMS reports that
the patient was visiting her sister from out of town and has been in her usual state of health up
until that morning when she began feeling short of breath and developed mid-sternal chest
pain. When she stood up this morning, she felt light-headed and abruptly sat back down and
called 911. Upon EMS arrival, the patient was alert and oriented but appeared in acute
distress. Her vital signs initially revealed a blood pressure of 96/54 mm Hg, a heart rate of 95
bpm, a respiratory rate of 28, and an oxygen saturation of 79% on room air. She had coarse
breath sounds throughout, had palpable pulses in all four extremities, and showed no focal
neurologic deficits on their exam. EMS immediately obtained IV access in the patient’s right
antecubital fossa and started a 1-L bolus of normal saline. They placed her on a 4-L nasal
cannula with improvement of her oxygen saturation to 84%. EMS was able to obtain history
from the patient and her sister who was on the way to the emergency department by private
vehicle. Per EMS, the patient normally reports feeling a slight headache, body pains and an
intense feeling of flushing since starting Remodulin®. Today, she noted that she has not had
those symptoms. She denied headache, neck or back pain, radiation of her chest pain, fever,
chills, nausea, vomiting, or abdominal pain.
Upon arrival to the emergency department, the patient continues to appear in respiratory
distress and complains of mid-sternal chest pressure. During the history and physical, the
patient is more lethargic and reports that it is hard for her to breathe. The patient is unable to
provide further details due to increased work of breathing and lethargy. The patient’s medical
history is otherwise negative, and EMS was unable to obtain surgical history. The patient did
come with a medication list that includes Remodulin®, Adempas®, Opsumit®, and prednisone
daily. There is no history of illicit drug usage and no known medical allergies. 
Optimal management of this case begins with the learner obtaining a focused history from the
EMS team and patient. Pertinent positive details include the patient’s progressive shortness of
breath, chest pain, and feeling of pre-syncope prior to arrival. Pertinent negative details include
the sudden lack of sensation of her typical headache, body aches, and sensation of feeling
flushed. The learner should then appropriately execute a targeted physical exam starting with
the ABCs. Given the unique pathophysiology of PH patients, the learner will need to pay careful
attention to correct resuscitation efforts that improve abnormal vital signs and physical exam
findings. This includes stopping the IV fluids and ensuring appropriate, non-invasive means for
oxygenating the patient. They should keep a broad differential and order other diagnostic
studies like an electrocardiogram and chest X-ray. Learners should remain focused on the
resuscitation of the patient throughout the case and not be distracted by the Remodulin®
pump. Once initial stabilization efforts are achieved, the learner will need to promptly identify
the cause of the patient’s symptoms and abnormal vital signs by recognizing an error in the
Remodulin® delivery system. Early discussion with the hospital pharmacist or PH team should
be done to arrange for the patient’s medication (or similar medication) to be restarted via
peripheral or central IV access. Ultimately, IV access and the decision to provide appropriate
medication should occur within the initial 5 to 10 minutes of patient presentation.
If the patient is taken to the CT scanner at any time (with persistently abnormal vital signs),
rapid sequence intubation is performed, or the learner fails to recognize the need to restart the
medication from a different IV site, the patient undergoes cardiac arrest and the case is
terminated after a few additional minutes per the discretion of the teaching faculty member. We
defer to the individual clinical experts when there are cases in which some missteps in
management occur but the IV Remodulin is restarted. However, given the complexity of the
case, we would lean towards successful management in most of those scenarios.
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Debriefing
To complete the learning exercise, a debriefing session for all simulation participants was
hosted immediately after termination of the case. Learners were challenged to review their own
performance through an advocacy-inquiry debriefing approach. The team was also asked to
reflect on their interprofessional communication and their clinical approach to an
undifferentiated, unstable patient.
The main discussion focused on the management of the crashing PH patient with abnormal
vital signs. The generation of a broad differential to guide workup and treatment served as the
initial focus of the discussion as many learners were unfamiliar with this unique patient
population. Deciphering normal from abnormal vital signs in PH patients was an area of
difficulty for many learners due to limited knowledge of the baseline physiology for this patient
population. Furthermore, resuscitation priorities are very unique for PH patients given complex
hemodynamic balances. For example, in PAH and right ventricular dysfunction
patients, hypotension typically represents hypervolemia, unless given a strong history of
dehydration.
The discussion then switched to the Remodulin® pump itself and troubleshooting a faulty
machine and/or line. In our experience, a vast majority of the learners had never seen a
Remodulin® pump, let alone knew how to ensure proper functioning of an existing line.
Additionally, learners were unfamiliar with the types of medication classes these patients may
be taking, so a brief review of these concluded the debriefing.
Post-scenario didactics
After debriefing, the Remodulin® pump was circulated for residents to review and ask
questions about aspects of the medication delivery and pump functions. Discussion reinforced
key aspects and skills learned during the simulation. Emphasis was made around goals of
resuscitation including limiting the amount of IV fluids, maximizing non-invasive routes of
oxygenation, and identifying and treating sources of hypotension. Time was allotted at the end
for learners to ask further questions. Two weeks after the case was presented, a grand rounds
lecture was given by a member of the critical care faculty to reinforce knowledge and answer
further questions about PH patient resuscitation.
Discussion
PH is becoming an increasingly more common disease encountered by clinicians throughout
various practice environments. With the rising age and growing population in the United
States, it is expected that the number of PH patients will continue to grow. Clinicians in the
emergency settings must cultivate a solid knowledge base in the subtleties of PH resuscitation,
especially as advancements in acute therapies continue to increase. In our experience, many
emergency medicine residents lack a firm grasp of the intricacies that must be known when
caring for PH patients. Furthermore, there is a paucity of published information and didactics
on caring for the acute complications that PH patients face. Due to the dire consequences of
even slight missteps in treatment, simulation surrounding these topics will be essential for the
training of our current and future residents.
Our simulation is structured to represent a high-acuity situation involving the quick
decompensation of a hypotensive and tachycardic PH patient. We chose this case of medication
and pump failure because it highlights the four most important aspects of caring for PH
patients: fluid management and support of mean arterial blood pressure; airway management
through maximization of non-invasive modes of ventilation; management of vasoactive
medications (Remodulin®) and their abrupt cessation in the acute setting; and creation of a
2020 Wipprecht et al. Cureus 12(5): e8223. DOI 10.7759/cureus.8223 13 of 15
broad differential diagnosis including sepsis, heart failure, coronary artery disease, and other
etiologies of a shock state. Through this simulation, we found that learners were generally
unfamiliar with the Remodulin® pump and benefited from simulation activities surrounding its
use.
Conclusions
This case highlights the importance of education on the management of PH patients who
present to the acute care setting in extremis. Learners were trained how to construct and work
through a broad differential diagnosis and evaluate medication and pump failure. They
developed expertise in focusing resuscitation efforts to limit fluids, initiate vasopressors early,
emphasize non-invasive modes of ventilation, and avoid acidosis at all costs. Through high-
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